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Ischemia reperfusion injury (IRI) is an inevitable clinical consequence in organ transplantation. It can lead to early graft
nonfunction and contribute to acute and chronic graft rejection. Advanced molecular biology has revealed the highly complex
natureofthisphenomenonandfewdeﬁnitivetherapiesexist.ThispaperreviewsfactorsinvolvedinthepathophysiologyofIRIand
potential ways to attenuate it. In recent years, inhaled nitric oxide, carbon monoxide, and hydrogen sulﬁde have been increasingly
explored as plausible novel medical gases that can attenuate IRI via multiple mechanisms, including microvascular vasorelaxation,
reduced inﬂammation, and mitochondrial modulation. Here, we review recent advances in research utilizing inhaled nitric oxide,
carbon monoxide, and hydrogen sulﬁde in animal and human studies of IRI and postulate on its future applications speciﬁc to
solid organ transplantation.
1.Introduction
Organtransplantationisanestablishedtreatmentthatallows
patients suﬀering from end-stage organ diseases to start
livingtheirlifeanew.IntheUnitedStates,morethan100,000
patients are waiting for solid organ transplants, but less than
10% of patients have undergone the necessary transplanta-
tion. While the survival rate has increased substantially over
the past decade, according to the U.S. Organ Procurement
and Transplantation Network and the Scientiﬁc Registry
of Transplant Recipients, morbidity and mortality remains
substantial. With the shortage of organs, it is clear that treat-
ments need to be developed to optimize the quality of the
organs that are available and to attenuate injury to trans-
planted organs.
Ischemia reperfusion injury (IRI) remains a critical clin-
ical issue in organ transplantation. It can result in a higher
incidence of acute and chronic rejection, as well as long-
termmorbidityandmortality[1,2].Ischemiaisaninevitable
event, starting with the cessation of arterial blood ﬂow
after organ procurement, cold ischemic time of the organ
being donated, and warm ischemic time of the recipient
during the organ transplantation. Reestablishment of blood
ﬂow in transplant recipients results in reperfusion injury,
which is characterized by oxidative stress and inﬂammation
(Figure 1). Much interest has been shown recently, not only
in microcirculatory ﬂow disturbances, but also in the pa-
thophysiology of IRI in terms of the intracellular and
molecular mechanisms.
A class of signaling molecules called “gasotransmitters”
has been investigated as a supplementary therapeutic agent
during solid organ transplantation. These medical gases,
nitric oxide (NO), carbon monoxide (CO), and hydrogen
sulﬁde (H2S), have traditionally been considered to be toxic
and environmentally hazardous. However, numerous exper-
imental animal and human studies of these agents have
demonstrated protective eﬀects against IRI. The aim of this
reviewis to summarize the current understanding of medical
gasesonattenuationofthepathophysiologyIRIinthesetting
of organ transplantation.2 Journal of Transplantation
2. Ischemia and Reperfusion Injury in
OrganTransplantation
Ischemia reperfusion injury is an occurrence where injury to
an organ occurs during times of hypoxia and is ampliﬁed
when blood ﬂow (oxygen) is reestablished. Injury can be
incurred during both phases of ischemia (warm and cold)
[3]. Warm ischemia occurs at the time of organ procurement
and reperfusion during transplantation when blood ﬂow is
restored. Cold ischemia occurs during the time of storage in
preservation solution prior to the anticipated transplant [4].
Warm ischemia leads to the activation of a multitude
of immunoinﬂammatory pathways culminating in cellular
injury to a particular organ, but also systemically [5]. Warm
IRI can be divided into early and late phases. The early phase
occurs within the period of the ﬁrst two hours of reperfusion
and the late phase generally described as occurring within
6–48 hours after reperfusion. During the early phase,
signiﬁcant activation of immune cells occurs with resultant
formation of reactive oxygen species (ROS). The late phase
is characterized by neutrophil-mediated organ injury that
occurs as a consequence of early phase consequences and net
cumulative eﬀect of the overlap of both phases [6].
More speciﬁcally, each organ is subjected to a particular
sequence of inﬂammatory events leading to injury. For
example in the liver, Kupﬀer cells, the resident macrophages
appear to be instrumental in orchestrating injury during the
early phase of IRI. These cells are major producers of ROS
that not only leads to local injury but serves as substrate for
other inﬂammatory reactions that inﬂict both local and sys-
temicinﬂammatoryinjury.Thisincludescellularinjuryfrom
lipid peroxidation, DNA damage, and enzyme denaturation.
GenerationofROSnotonlyleadstodirectcellularinjurybut
serves to activate other immune cell lines that hone in neu-
trophils. Cytokine and chemokine production occurs also
during the early phase of IRI. For example, tumor necrosis
factor-alpha (TNF-α) and interleukin-1 (IL-1) signiﬁcantly
increase early systemically in the serum just minutes after
reperfusion. Interestingly, these cytokines along with others
upregulate the production of other cytokines, chemokines,
and adhesion molecules, all critical to the pattern of injury
observed in the late phase of IRI [7].
Chemokines and adhesion molecules recruit neutrophils
and other immune cells to the site of injury. Chemokines
vital to this process include interleukin-8, and macrophage
inhibitoryproteins.Cellsthatreleasethesemoleculesinclude
resident macrophages, endothelial cells, and organ-speciﬁc
parenchymal cells. Various adhesion molecules are required
to the transmigration of the neutrophils journey via the
bloodstream to the sites of ischemic organ injury. This is
facilitated by the upregulated expression of selectins, inte-
grins, and immunoglobulins, all which ultimately lead to the
accrual of neutrophils and platelets within organ parenchy-
ma resulting in late phase IRI [8].
Neutrophils themselves when primed by a proinﬂam-
matory stimulus are highly active and release proteases and
other cytotoxic substances. Neutrophils are also responsible
for the release of clinically signiﬁcant concentrations of
ROS through nicotinamide adenine dinucleotide phosphate
Figure 1: Preemptive treatment with inhaled nitric oxide, carbon
monoxide and hydrogen sulﬁde can attenuate ischemia-reperfusion
injury via modulation of a myriad of inﬂammatory, cellular and
vascular mechanisms. GTP: guanosine triphosphate, GC: guanylate
cyclase, cGMP: cyclic guanosine monophosphate, MAPK: mitogen-
activated protein kinase, ERK: extracellular signal-regulated kinase,
JNK: c-Jun N-terminal kinase, p38: a class of mitogen-activated
complexes, iNOS: inducible nitric oxide synthase (iNOS), NFkB:
nuclear factor kappa B, STAT-3: signal transducer and activator of
transcription3,ATP:adenosinetriphosphate,Nrf-2:nuclearfactor-
like 2, Hif: hypoxia inducible factor, and GSH: glutathione.
hydrogen (NADPH) oxidase-dependent pathway. Activation
of this enzyme system results in the predominant production
of superoxide radical that in itself induces injury but also
serves as substrate for a multitude of other proinﬂammatory
reactions.
Not all of the pathways activated during the ischemia and
reperfusion are injurious. Several pathways have been iden-
tiﬁed to limit injury. One of the most commonly referenced
is the heme oxygenase (HO) system that is triggered due to
the formation of ROS resulting in heme breakdown [9]. It
is the heme breakdown products (a more neutral reduced
iron), carbon monoxide (CO), and biliverdin that in their
own dissimilar ways result in organ protection during IRI.
The therapeutic utilization of CO will be discussed in more
detail and is an obvious focus of this concise review.
Injury suﬀered during cold ischemia has been demon-
strated to be diﬀerent from warm and is directed toward in-
jury to the endothelial cells and microcirculation as opposed
to direct damage to the organ parenchymal cells. Endothelial
cells seem to be more susceptible to cold storage compared
to parenchymal cells [10]. Previous studies have shown that
c e l ld e a t hi sm u c hg r e a t e ri ne n d o t h e l i a lc e l l sc o m p a r e d
to parenchymal cells at the same time points. The injury
appears to occur due to activation of apoptotic and necrotic
pathways. In livers, the degree of injury has been shown
to correlate with graft function following reperfusion. And
overall, generalized inﬂammatory pathways involved in both
early and late warm IRI seem to be enhanced with increasing
cold storage times.Journal of Transplantation 3
The pathogenesis of IRI is also signiﬁcantly inﬂuenced
by toll-like receptors (TLRs) (Figure 2)[ 11]. These receptors
are transmembrane proteins which form the major pattern
recognition receptors that transduce signals in response to
diverse pathogen-associated molecular patterns (PAMPs).
There are a variety of TLRs (TLR 1–7,9) with each of them
recognizing distinct PAMPs with their activation leading to
the initiation of innate and adaptive responses through the
upregulation of cytokines, chemokines, and others immune
cells. Once TLRs are ligated, they undergo conﬁrmational
change and recruit cytoplasmic adapter proteins (Figure 2).
The proximal adaptor proteins that mediate TLR signaling
are myeloid-diﬀerentiation primary response gene 88
(MyD88). Downstream of MyD8, regulatory kinases are
recruited, ultimately leading the activation of NF-κB, ERK
and/or activation of mitogen activation protein kinase
pathways (MAPK). The net eﬀect of activating these path-
ways enhanced production of inﬂammatory mediators thus
injury.
Apoptosis or controlled program cell death is a major
occurrence of IRI during organ transplantation [12]. Apop-
tosis pathways are activated and regulated between a multi-
tude of signals. It has been demonstrated that organs com-
monly transplanted including liver, commonly incur allo-
graft cellular apoptosis. During reperfusion both endothelial
cells and parenchymal cells are susceptible to apoptosis.
Many previous studies have depended on the TUNEL (ter-
minaldeoxynucleotidyltransferase-mediateddUTPnickand
end labeling) assay to characterize apoptosis. This technique
has been shown to stain any cell with DNA strand breaks
irrespective of whether the mechanism of cell death was
apoptosis or necrosis. Since the institution of more speciﬁc
techniquestoassistinidentifyingapoptoticcells,theabsolute
numbers of cells being aﬀected by IRI during organ trans-
plantation are probably not as high as previously thought.
Many of the cells thought previously to have been apoptotic
were probably necrotic. These necrotic cells probably lead
to enhanced inﬂammation via activation of complement
and generation of ROS. One important mediator speciﬁcally
released by necrotic cells is high mobility group box 1
(HMGB1). HMGB1 is a nuclear factor bound to chromatin
that during warm ischemia has been shown to bind to
TLR4 and stimulate proinﬂammatory cytokine release. Pre-
viously, inhibition of HMGB1 attenuated cytokine release
and reduced neutrophil inﬁltration in a model of liver IRI.
T h ep r e v i o u sp a r a g r a p h sa r eab r i e fs u m m a r yo ft h e
pathwaysinvolved in IRIand serve astoassist in understand-
inghowtheaforementionedinhaledmedicalgasesmayassist
in attenuating IRI during organ transplantation.
3.MedicalGasesandOrgan Transplantation
The gases NO, CO, and H2S have been recognized as im-
portant signaling molecules. They regulate vascular tone and
ameliorate inﬂammatory eﬀects. Traditionally, these gases
have been regarded as toxic and lethal. However, many stud-
ies have established that these gases are safe and at lower con-
centrations possess beneﬁts in attenuating IRI in the setting
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Figure 2: Toll-like receptor (TLR): mediated pathway during IRI.
Ligation of the TLR leads to activation of upstream MyD88 and
activation downstream NF-κB, p38 and JNK pathways resulting in
cellular injury. SEC: sinusoidal endothelial cells, DAMP: damage-
associated molecular proteins [10].
organ transplantation. To date, there are an increasing num-
ber of reports on the role of medical gases in mitigating IRI.
4.NO andOrganTransplantation
Inhaled NO (iNO) was approved by the U. S. Food and
Drug Administration in December 1999 for the treatment of
persistenthypertensionofthenewborn.Overthelastdecade,
the primary advantage of iNO has been its ability to selec-
tively decrease pulmonary vascular resistance with minimal
eﬀects on systemic blood pressure. However, there is cur-
rently much interest in exploring its other beneﬁts, including
its antioxidant properties and cytoprotective abilities.
Nitric oxide was ﬁrst identiﬁed as an endothelium-
derived relaxing factor. Since then, it has been recognized for
its eﬀects as an antioxidant, an antiapoptotic agent, as well
as its ability to inhibit adhesion molecules [13]. All of these
properties contribute to its eﬀectiveness in attenuating IRI.
Nitrite (NO2
−), which is reduced to NO during ischemia,
protects mitochondria from IRI by blocking complex I of the
electron transport chain, thereby limiting ROS generation
and cytochrome c release [14] .T h ec y t o p r o t e c t i v ee ﬀect of
nitrite in cardiac and hepatic ischemia-reperfusion in mice
demonstrates the potential for nitrite, in addition to inhaled
NO, to be used as treatment to modulate IRI [15]. Head-
to-head prospective comparisons assessing mechanism and
clinically relevant endpoints should be encouraged.
The quality and viability of an organ to be transplanted
is of primary concern. With thousands of patients on organ
transplantation waiting lists, it is critical to enlarge the pool
of usable organs and to more predictably mitigate IRI in the
donor organ. The use of nonheart-beating donors (NHBDs)
would expand the donor pool, but the additional cellular
damage that is incurred during warm ischemia may render
these organs unusable. If however, these otherwise poorer4 Journal of Transplantation
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Figure 3: iNO decreases reperfusion-dependent hepatic cell death. (a) Histopathologic scoring of hepatic tissue samples before (white bars)
and 1 hour after reperfusion (black bars). P-values represent signiﬁcance calculated by paired t test. (b) Representative H&E-stained sections
indicating increased injury in LB2. Original magniﬁcation ×25. The circled area is shown at a higher magniﬁcation (×100) in the inset
and shows increased PMN inﬁltration adjacent to the hepatic vein (zone 3). (c) Representative ﬂuorescence micrographs showing changes
in TUNEL-positive cells (green); blue staining: DAPI. Original magniﬁcation, ×25. (d) Paired changes in TUNEL-positive objects in liver
biopsies before (LB1) and 1 hour after reperfusion (LB2). P values represent signiﬁcance calculated by paired t-test. (e) Average reperfusion-
dependent increases in TUNEL-positive objects. ∗P ≤ 0.0005 relative to placebo [17].
quality organs could be salvaged, more patients could receive
transplants. In a rat model of lung transplantation using
NBHDs, the treatment of donors with NO during ischemia,
ex vivo perfusion, and after transplant resulted in better
oxygenation and reduced pulmonary vascular resistance
[16]. A similar NO treatment could easily be translated to
human transplant patients in order to see an improvement
in lung function.
Inhaled NO has been shown to be safe and eﬃcacious in
human trials. In a prospective, blinded, placebo-controlled
study, 80ppm of iNO was administered to 10 out of 20
patients undergoing orthotopic liver transplantation. Many
advantages were reported in the iNO group, including
reduced platelet transfusion, an improvement in the rate at
which liver function was restored after transplantation, and a
decreaseinthelengthofhospitalstay(Figure 3)[17].AlargerJournal of Transplantation 5
trial enrolling 80 patients is currently underway in order to
conﬁrm these results. [Add in unpublished data].
Organ rejection is a critical concern with any transplant.
Inhaled NO has also been used eﬀectively in preventing
allograftdysfunction.TreatmentwithiNOinlungtransplant
patients postoperatively was shown to improve oxygenation
and decrease pulmonary artery pressure. No complications
were associated with the use of NO, and the mortality rate
was reduced [18]. Likewise, a retrospective study of patients
who received iNO before or after transplantation also pre-
sented an improvement of overall respiratory functions [19].
However, in a randomized, placebo-controlled study of 84
patients who received NO or nitrogen following lung trans-
plantation, no diﬀerences were found between the treatment
and control groups [20]. In this latter study, iNO was
administered at a concentration of 20ppm while the other
two studies started at 40ppm and gradually reduced NO
concentrations. Clearly, additional prospective randomized
studies are necessary to further evaluate the most eﬀective
levels of iNO usage. But it is signiﬁcant to note that no
adverse side eﬀects were associated with the use of inhaled
NO in any of the clinical trials [17–20].
5.COandOrgan Transplantation
Carbon monoxide is a lethal gas when inhaled in high con-
centrations for long periods of time. CO avidly binds to
hemoglobin and forms carboxyhemoglobin (COHb) with
an aﬃnity more than 200 times higher than of oxygen. As
a result, the blood’s oxygen-carrying capacity is impaired,
which eventually causes tissue hypoxia. Because of their high
metabolic rate, the brain and the heart are the most sensitive
to CO exposure [21].
Humans and animals actually produce carbon monoxide
endogenously [22]. In humans, CO arises from the action of
microsomal heme oxygenase (HO) enzymes, which catalyze
the conversion of heme into equimolar amounts of iron,
biliverdin, and CO. HO has three isoforms: HO-1 (also
known as heat shock protein 32), HO-2, and HO-3. Of
the three isoforms, only HO-1 is inducible in response to a
variety of cytokines and growth factors, as well as hypoxia
and oxidative stress [23] .T h eC Ot h a ti sp r o d u c e db y
HO enzymes has multiple physiological eﬀects, including
vasodilation [24], anti-inﬂammatory, and antiapoptotic
eﬀects (Figure 4)[ 25, 26].
The known eﬀects of carbon monoxide on the vascu-
lature and on apoptosis make it an intriguing molecule
to test in clinical models of IRI. Both inhaled CO and
CO-releasing molecules (CO-RMs) have been shown to be
eﬀective in protecting rat hearts from IRI injury, resulting
in less inﬂammation, less apoptosis, and less endothelial
damage[27,28].Similarly,whenratliverswereperfusedwith
CO-supplemented blood or preserved in a CO-containing
solution, they exhibited less hepatocyte histologic injury and
a reduction in neutrophil extravasation, and they had an
increased survival rate [29, 30]. There is also evidence that
CO reduces delayed graft function in swine kidneys [31]a n d
may prevent graft rejection [32].
Figure 4: Gross anatomy of lungs from rats 6 days after trans-
plantation (arrow in a, b) and lungs from rats 6 days after
transplantation which received CO at 500ppm. In (a) and (c), the
arrow points to the left transplanted lung; the right lung is the
remaining native lung. Note that in the absence of CO, transplanted
lungs were noted to be markedly hyperemic (a) and (b), which was
notably absent in the transplanted lung exposed to CO (c) and (d).
Scale bar, 1cm [26].
Despite the success of CO therapy in animal studies,
the utility of CO as therapy in humans is uncertain. In
unpublished data, CO in Phase I trials has been shown to be
well tolerated with no signiﬁcant adverse eﬀects compared
to placebo [33]. Further human clinical trials should be
conducted cautiously in order to determine therapeutic
doses and routes of administration. In fact, a Phase II trial
is in progress that investigates the ability of CO to attenuate
IRI in kidney transplantation with the focus of assessing the
inﬂuence of delayed graft dysfunction.
6. H2SandOrganTransplantation
Like NO and CO, hydrogen sulﬁde is primarily thought of
as a toxic gas. Its reputation is well earned, for those who
inhale it suﬀer from a range of eﬀects, including mucosal ir-
ritation, memory loss, respiratory paralysis, and, sometimes,
death. What is less known is that H2S naturally occurs in
mammalian tissue as a byproduct of cysteine metabolism. Its
production from L cysteine is catalyzed by cystathionine-β-
synthase(CBS),cystathionine-γ-lyase(CSE),or3-mercapto-
pyruvate sulfurtransferase (3MST). 3MST is the major H2S-
forming enzymes in the brain while CSE is a principle H2S-
forming enzyme in the cardiovascular system [34–36]. In
other organs, such as the liver and the kidney, both enzymes
contribute to H2Sp r o d u c t i o n[ 37].6 Journal of Transplantation
0
5 1 01 53 06 0 9 01 2 0 1 8 0
20
40
60
80
100
120
Control
Hydrogen sulphide
Reperfusion time (min)
R
B
F
 
(
m
L
/
m
i
n
/
1
0
0
 
g
)
(a)
123
0
1200
1000
800
600
400
200
Control
Hydrogen sulphide
∗
∗ ∗
Before reperfusion
Reperfusion time (h)
C
r
e
a
t
i
n
i
n
e
 
(
μ
m
o
l
/
L
)
(b)
0
500
1000
1500
Control
Hydrogen sulphide
Total
U
r
i
n
e
 
o
u
t
p
u
t
 
(
m
L
)
1 h 2 h 3 h
(c)
Figure 5: Indices of renal function were enhanced with hydrogen sulphide treatment. (a) Mean renal blood ﬂow (RBF) over 3hrs of re-
perfusion (b) Mean (s.d.) serum creatinine level over 3hrs of reperfusion. ∗P<0.050 versus control (Mann-Whitney U test) (c) Urine
output at each hour of reperfusion [46].
The distinctive rotten-egg odor of H2S gives no indica-
tion of its therapeutic potential. Nevertheless, endogenous
and exogenous H2Sh a v eb e e ns h o w nt or e d u c em y o c a r d i a l
infarct size in various animal models when administered
prior to reperfusion [38–42]. The cardioprotective eﬀects
are partially a result of the scavenging of hydrogen peroxide
and free radicals [36, 43] and by the preservation of
mitochondrial function [42]. H2S also attenuates IRI by
dilating blood vessels through the opening of ATP-sensitive
K+ (KATP) channels in vascular smooth muscle [39, 44]. This
protection against ischemic damage has been demonstrated
in the liver [45], and kidney [46, 47], as well.
With a low dose of hydrogen sulﬁde, mice enter a sus-
pended-animation state with a reduced metabolic rate and
lower core body temperature [48]. This artiﬁcial means of
inducing a hypothermic-like state had no apparent adverse
eﬀects; thus, the potential exists to take advantage of this re-
ducedmetabolic usageto improve organpreservation. When
an H2S donor was added to the preservation solution in an
ex vivo rat liver model, the damaging eﬀects of cold storage
werepartiallyreversed[49].I namousemod elofr enaltrans-
plantation, treatment with H2S during the hypoxic stage of
I R Ir e s u l t e di nd r a m a t i c a l l yr e d u c e dr e n a ld a m a g e( Figure 5)
[49, 50]. The apparent mechanism for prevention of renal
injury is by reversible inhibition of cytochrome c oxidase,
the terminal enzyme of the mitochondrial electron transport
chain[1,50].Thesedatacombinedprovideacompellingcase
for the further exploration of H2S usage in the attenuation
and prevention of ischemia-reperfusion injury. Currently,
there has not been any testing of H2S in human subjects, but
the data from animal models is intriguing, and clinical trials
are necessary to validate the eﬃcacy of H2S.
7. MedicalGasesAdministeredinCombination
The authors are unaware of studies performed in animals
or in humans to determine the combined eﬀects of the
aforementioned gasotransmitters. It is unclear what eﬀect
combination therapy may elicit. However, both NO and CO
are known to inhibit platelets by mediating a decrease in
intraplatelet calcium via cGMP signaling. The eﬀect of H2S
on platelets has not been elucidated, but it is also believed to
beaplateletinhibitor[51].Apossiblecomplicationoftheuse
of multiple gasotransmitters during transplantation could be
increased bleeding or a need for platelet transfusion during
surgery. It should be noted, though, that the use of NO as a
single agent decreased the frequency of platelet transfusions
during liver transplantation [20], so the possibility of
increased bleeding with medical gas combination treatment
may be quite small.
8. Conclusions and Perspectivesfor the Future
Administration of medical gases, speciﬁcally NO, CO,
and H2S, has been shown to mitigate IRI during organJournal of Transplantation 7
transplantation because these gases ameliorate oxidative
stress, stimulate vascular smooth muscle cell relaxation, and
reduce inﬂammation and apoptosis. From an optimistic
viewpoint, these gases would decrease acute and chronic
organ rejection, thereby increasing the quality of organ
transplantation. Because there are currently no other thera-
pies being utilized that increase the quality of transplanted
organs, the further testing of these gases is crucial to
improving the pool of potential donor organs. However, the
treatments are in their infancy, and more clinical trials are
needed to determine the indications, therapeutic doses, and
optimal times of administration as well as adverse eﬀects.
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